Загрузка...
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
PURPOSE: A phase I clinical study was conducted to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan hydrochloride (CPT-11) in CPT-11/pegylated liposomal doxorubicin (PLD) combination therapy, a novel treatment regimen for platinum- and taxane-resistant recurrent...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4000409/ https://ncbi.nlm.nih.gov/pubmed/24585045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2418-8 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|